Making a difference with your help.
Protocol Name: SPARX: Safety and efficacy of sparsentan for patients post kidney transplantation with IgAN or FSGS Protocol #: TVTX-RE021-426 Indication: Cardiovascular Event Risk Reduction GFR: ≥25 Principal Investigator: Bernard Fischbach, MD, CCRP Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Protocol Name: AZURE: Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event Protocol #: D7960C00015 Indication: Cardiovascular Event Risk Reduction GFR: ≥15 Principal Investigator: Ankit N. Mehta, MD, FASN Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas,
Protocol Name: ZENITH: Zilebesiran in Patients with HTN not Adequately Controlled and with either Established CVD or at High Risk for CVD Protocol #: ALN-AGT01-008 Indication: HTN (Uncontrolled) GFR: <60 Principal Investigator: Ankit N. Mehta, MD, FASN Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >
Protocol Name: Observational Study of Safety and Effectiveness of Elfabrio in Fabry Patients Protocol #: CLI-06657AA1-10 (MODERN) Indication: Fabry Disease GFR: n/a Principal Investigator: Ankit N. Mehta, MD, FASN Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Observational Study of Safety and Effectiveness of Elfabrio in Fabry Patients Read More »
Protocol Name: Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype Protocol #: MZE829-201 Indication:APOL1-Mediated Proteinuric Kidney Disease GFR: ≥25 Principal Investigator: Tapan J. Patel, MD, FACP, FASN, FNKF Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas,
Protocol Name: Trial to Evaluate the Long-term Safety and Efficacy of Avacopan in Subjects With ANCA-associated Vasculitis Protocol #: 20220159 Indication: ANCA associated Vasculitis GFR: ≥15 Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Protocol Name: Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants with APOL1-Mediated Kidney Disease Protocol #: D6800C00005 Indication: APOL1-Mediated Proteinuric Kidney Disease GFR: ≥ 25 Principal Investigator: Akinwande Akinfolarin Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >
Protocol Name: Does aldosterone synthase inhibition prevent kidney disease progression, heart failure or cardiovascular death? Protocol #: EASi-Kidney Indication: CKD GFR: 20-90 DETAILS >
Protocol Name: Phase 2b Open-label Study of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease Protocol #: VX24-147-202 Indication: APOL1-Mediated Proteinuric Kidney Disease GFR: ≥25 to ≤75 Principal Investigator: Bernard Fischbach, MD Location: Landry Center, 411 N. Washington Ave, Suite #6000, Dallas, TX 75246 DETAILS >
Protocol Name: Observational Study Protocol – Fabry Disease Registry Protocol #: DIREGC07006 Indication: Fabry Disease Principal Investigator: Ankit Mehta, MD Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >
Observational Study Protocol – Fabry Disease Registry Read More »